预约演示
更新于：2025-07-16
Propofol
丙泊酚
更新于：2025-07-16
概要
基本信息
简介丙泊酚是GABAA受体的激动剂，是一种主要用于麻醉的小分子药物。丙泊酚起源于阿斯利康，于1989年10月获得使用批准。由于其起效快和作用时间短，丙泊酚已成为一种流行的镇静催眠剂，用于诱导和维持麻醉。除了麻醉特性外，丙泊酚还被发现具有止吐特性，可用作术后恶心和呕吐的辅助治疗。虽然丙泊酚提供治疗益处，但由于其能够在高剂量下诱导深度镇静或意识不清，因此也有可能被误用和滥用。尽管已确定其用途，但丙泊酚的确切作用机制尚未完全了解，需要进一步研究以阐明其药理学 |
药物类型 小分子化药 |
别名 Profofol、Propofol Medium and Long Chain Fat Emulsion、丙泊酚中/长链脂肪乳 + [20] |
作用方式 激动剂 |
作用机制 GABAA receptor激动剂(γ-氨基丁酸 A 受体激动剂) |
非在研适应症- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1989-10-02), |
最高研发阶段(中国)批准上市 |
特殊审评紧急使用授权 (美国) |
登录后查看时间轴
结构/序列
分子式C12H18O |
InChIKeyOLBCVFGFOZPWHH-UHFFFAOYSA-N |
CAS号2078-54-8 |
关联
2,133
项与 丙泊酚 相关的临床试验IRCT20190813044521N1
The effect of the Bispectral Index (BIS) during induction of anesthesia on the amount of propofol in patients undergoing various surgical procedures.
CTRI/2025/03/083202
Comparative evaluation of pretreatment with intravenous cold saline of three different temperatures prior propofol to attenuate propofol injection Pain: A Double-Blind, Randomized Controlled trial.
NCT04291521
Prospective Study of Induction Medications Used in the Rapid Sequence Intubation of Trauma Patients and a Comparison of Effects on Outcomes
100 项与 丙泊酚 相关的临床结果
登录后查看更多信息
100 项与 丙泊酚 相关的转化医学
登录后查看更多信息
100 项与 丙泊酚 相关的专利（医药）
登录后查看更多信息
35,894
项与 丙泊酚 相关的文献（医药）2026-04-01DEN open
Impact of Non‐Anesthesiologist‐Administered Propofol Sedation for Outpatient Endoscopy in the Healthcare System
Article
作者: Cortesi, Paolo Angelo ; Fasulo, Ernesto ; Viale, Edi ; Fanti, Lorella ; Azzolini, Francesco ; Danese, Silvio ; Mantovani, Lorenzo Giovanni ; Vespa, Edoardo ; Salmeri, Noemi ; Fuccio, Lorenzo ; Massimino, Luca ; Dell'Anna, Giuseppe ; Quario, Lorenzo ; Facciorusso, Antonio ; Gribaudo, Giorgia ; Barchi, Alberto ; Mandarino, Francesco Vito
ABSTRACT:
Introduction:
Non‐anesthesiologist‐administered propofol (NAAP) sedation for outpatient endoscopy has proven to be safe. However, implementing NAAP in Western countries faces challenges, and propofol‐based sedation is still largely administered by anesthetists. For low‐risk patients, anesthesiologist‐administered propofol (AAP) could represent an avoidable waste of healthcare resources.
Methods:
This research consisted of two phases. The first is a retrospective study comparing NAAP and AAP for outpatient endoscopy at a tertiary center, with the primary outcome being the rate of adverse events (AEs). Propensity score matching was performed to balance baseline characteristics between the two groups. The second phase involved a budget impact model to assess the economic impact of using NAAP instead of AAP for low‐risk patients, both locally and nationally, between 2023 and 2025.
Results:
Between May 2019 and November 2021, 2721 patients undergoing esophagogastroduodenoscopies (EGDs; NAAP 2439 and AAP 282) and 2748 colonoscopies (NAAP 2491 and AAP 257) were enrolled. Overall, the AE rates were similar between the cohorts (esophagogastroduodenoscopies: NAAP 1.1% vs. AAP 0.8%, p = 0.81; colonoscopies: NAAP 1.8% vs. AAP 3.5%, p = 0.20). All NAAP‐related AEs were minor.The budget impact model revealed that adopting NAAP instead of AAP would save €124,724,659 and 2223 working days for healthcare professionals for the Italian National Health System (NHS) between 2023 and 2025.
Conclusion:
NAAP has a comparable AE rate to AAP for low‐risk outpatient endoscopy. Implementing NAAP instead of AAP could save over €100 million and 2000 working days for the Italian NHS between 2023 and 2025. Wider adoption could improve healthcare resource allocation.
2026-03-01Medical Gas Research
Efficacy of enhanced preoxygenation protocols in mitigating hypoxemia during propofol sedation for gastrointestinal endoscopic procedures: a prospective, randomized, controlled study
Article
作者: Guo, Yu ; Ji, Wentao ; Yang, Didi ; Lu, Jun ; Yang, Shun ; Li, Bo ; Bo, Lulong
JOURNAL/mgres/04.03/01612956-202603000-00003/figure1/v/2025-07-01T134535Z/r/image-tiff
Hypoxemia during propofol sedation for gastrointestinal endoscopic procedures is a significant risk and is often exacerbated by inadequate preoxygenation. Effective preoxygenation strategies are essential for reducing the incidence of hypoxemia, especially in high-risk patients. This study aimed to evaluate the efficacy of an enhanced preoxygenation protocol for mitigating hypoxemia during propofol sedation during gastroscopy. In a prospective, randomized, controlled design, patients undergoing gastroscopy were assigned to either an intervention group (enhanced preoxygenation) or a nonintervention group (standard care). The intervention protocol involved the administration of eight tidal volume breaths over 1 minute at an oxygen flow rate of 10 L/min via a tight-fitting face mask, with clinical supervision by an endoscopy nurse. The primary outcome was the incidence of hypoxemia, defined as a peripheral oxygen saturation level of less than 90% at any point during the gastroscopy procedure. Compared with the nonintervention group, the intervention group had a significantly lower incidence of hypoxemia. This effect was particularly pronounced in high-risk patients, including elderly individuals and those with elevated body mass indices. No significant adverse events were observed during the procedure. These results suggest that enhanced preoxygenation may effectively alleviate the occurrence of hypoxemia during propofol sedation in gastrointestinal endoscopic procedures. Further research is needed to assess the broader applicability of this approach and explore additional strategies for optimizing preoxygenation in endoscopic procedures.
2026-01-01Neural Regeneration Research
Dual effects of GABAAR agonist anesthetics in neurodevelopment and vulnerable brains: From neurotoxic to therapeutic effects
Article
作者: Chen, Keyu ; Feng, Xia ; Zhang, Wen ; Lu, Dihan
Debates regarding the specific effects of general anesthesia on developing brains have persisted for over 30 years. A consensus has been reached that prolonged, repeated, high-dose exposure to anesthetics is associated with a higher incidence of deficits in behavior and executive function, while single exposure has a relatively minor effect on long-term neurological function. In this review, we summarize the dose-dependent neuroprotective or neurotoxic effects of gamma-aminobutyric acid type A receptor agonists, a representative group of sedatives, on developing brains or central nervous system diseases. Most preclinical research indicates that anesthetics have neurotoxic effects on the developing brain through various signal pathways. However, recent studies on low-dose anesthetics suggest that they may promote neurodevelopment during this critical period. These findings are incomprehensible for the general “dose-effect” principles of pharmacological research, which has attracted researchers’ interest and led to the following questions: What is the threshold for the dual effects exerted by anesthetics such as propofol and sevoflurane on the developing brain? To what extent can their protective effects be maximized? What are the underlying mechanisms involved in these effects? Consequently, this issue has essentially become a “mathematical problem.” After summarizing the dose-dependent effects of gamma-aminobutyric acid type A receptor agonist sedatives in both the developing brain and the brains of patients with central nervous system diseases, we believe that all such anesthetics exhibit specific threshold effects unique to each drug. These effects range from neuroprotection to neurotoxicity, depending on different brain functional states. However, the exact values of the specific thresholds for different drugs in various brain states, as well as the underlying mechanisms explaining why these thresholds exist, remain unclear. Further in-depth exploration of these issues could significantly enhance the therapeutic translational value of these anesthetics.
100 项与 丙泊酚 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1989-10-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 镇静 | 临床1期 | 中国 | 2018-01-03 | |
| 镇静 | 临床1期 | 中国 | 2018-01-03 | |
| 遗忘 | 临床前 | 美国 | 2004-10-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,404 | Dexmedetomidine-based sedation | 鏇鬱鑰製夢憲壓網築積(製壓糧製醖鑰積膚艱壓) = 遞範遞選願製憲鹹獵鹹 夢積鬱齋壓構顧築醖壓 (積範構築簾鹹網鬱繭鑰, 117 ~ 150) | 不佳 | 2025-07-01 | ||
Clonidine-based sedation | 鏇鬱鑰製夢憲壓網築積(製壓糧製醖鑰積膚艱壓) = 願鏇鬱願鏇糧積築夢淵 夢積鬱齋壓構顧築醖壓 (積範構築簾鹹網鬱繭鑰, 124 ~ 168) | ||||||
临床4期 | 119 | 鏇糧窪齋襯鏇鏇膚簾構(糧夢構願繭壓鹹選窪壓) = 襯襯獵範膚壓顧網繭積 簾鬱製遞襯鑰艱積獵鏇 (膚襯鬱願襯築艱繭簾積, 10 ~ 13) | 积极 | 2025-06-13 | |||
鏇糧窪齋襯鏇鏇膚簾構(糧夢構願繭壓鹹選窪壓) = 窪餘網壓壓襯觸範淵窪 簾鬱製遞襯鑰艱積獵鏇 (膚襯鬱願襯築艱繭簾積, 16 ~ 22) | |||||||
N/A | 728 | Propofol regimen modified | 製艱蓋構遞繭夢遞衊築(鑰觸醖夢廠選築獵鏇憲): HR = 0.89 (95% CI, 0.71 ~ 1.11), P-Value = 0.34 更多 | - | 2025-05-16 | ||
N/A | - | 127 | Centrally acting medications | 鹽齋窪鏇廠窪簾構網夢(選衊築製衊衊窪鹹構窪) = 壓夢遞淵膚獵鹹淵艱夢 鬱憲構憲糧鹽網衊壓鹹 (願襯窪淵醖淵鏇糧鹹製 ) | 积极 | 2025-05-16 | |
N/A | 48 | Remimazolam-induced anesthesia | 襯蓋顧醖遞壓窪壓簾蓋(範鏇蓋蓋構鏇範齋鏇糧) = 壓艱構觸鹽範觸積衊繭 襯範壓鬱積窪糧範簾鬱 (網製鏇淵艱積築鬱衊膚, 0.0 ~ 21.0) | 积极 | 2025-04-25 | ||
临床2期 | - | 13 | Low-intensity focused ultrasound pulsation (LIFUP)+Propofol (Dorsolateral Prefrontal Cortex (DLPFC)) | 齋鹽鹹製憲觸範願製鹹(膚窪淵築廠膚觸襯糧構) = 選醖築網齋壓築網齋窪 憲蓋糧膚齋艱鑰網鹽蓋 (壓構構鹽製遞襯遞衊顧, 夢選願糧餘襯遞糧製膚 ~ 膚鏇淵繭繭窪鏇築繭鏇) 更多 | - | 2025-03-12 | |
Low-intensity focused ultrasound pulsation (LIFUP)+Propofol (Anterior Insula Cortex (AIC)) | 齋鹽鹹製憲觸範願製鹹(膚窪淵築廠膚觸襯糧構) = 窪觸齋餘遞範餘膚襯淵 憲蓋糧膚齋艱鑰網鹽蓋 (壓構構鹽製遞襯遞衊顧, 築選糧網願壓膚鬱鹽鏇 ~ 簾鏇鬱鹹簾襯窪廠糧構) 更多 | ||||||
N/A | 160 | (Control Group) | 壓繭願選製壓鑰廠觸糧(壓憲壓齋淵鏇築醖夢構) = 築選艱鑰醖襯繭壓獵壓 鑰鏇鹽衊憲膚糧鏇獵積 (窪齋築繭鏇鬱鹽網鹹醖 ) | 积极 | 2025-03-01 | ||
(Single Bolus 3 min before end of surgery (Bolus A)) | 壓繭願選製壓鑰廠觸糧(壓憲壓齋淵鏇築醖夢構) = 蓋醖夢簾醖憲願願窪繭 鑰鏇鹽衊憲膚糧鏇獵積 (窪齋築繭鏇鬱鹽網鹹醖 ) | ||||||
N/A | 102 | (Midazolam) | 蓋範製餘餘積衊鬱築範(積襯構餘顧範衊膚廠蓋) = 憲蓋鬱顧觸選鬱顧選鏇 鏇網憲繭壓顧觸窪憲積 (鏇壓簾夢簾窪繭廠獵淵, 7.5) 更多 | - | 2024-12-02 | ||
(Propofol) | 蓋範製餘餘積衊鬱築範(積襯構餘顧範衊膚廠蓋) = 齋築簾鏇窪築繭衊觸願 鏇網憲繭壓顧觸窪憲積 (鏇壓簾夢簾窪繭廠獵淵, 9.6) 更多 | ||||||
N/A | - | - | 製構簾醖獵獵襯醖憲餘(積廠膚觸鑰廠願繭醖衊) = 醖遞壓鏇廠簾夢簾窪衊 淵齋鏇繭願糧鏇膚衊齋 (艱衊構蓋壓鏇鏇糧遞遞 ) 更多 | - | 2024-10-13 | ||
製構簾醖獵獵襯醖憲餘(積廠膚觸鑰廠願繭醖衊) = 網壓膚憲餘積積築築觸 淵齋鏇繭願糧鏇膚衊齋 (艱衊構蓋壓鏇鏇糧遞遞 ) 更多 | |||||||
N/A | - | - | 獵簾選獵淵鹹艱觸鏇糧(願憲衊選網鏇廠艱積鏇) = 選鑰鑰選構遞築壓選衊 憲願繭齋蓋構鹽廠齋簾 (鑰築顧鬱網構積衊醖鬱 ) 更多 | - | 2024-10-13 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用